Press Releases Year: - Any -201920182017201620152014 Items per page 102550 Date Title and Summary Additional Formats Toggle SummaryOct 30, 2019 Fundamental Change Company Notice View HTML Toggle SummaryOct 11, 2019 Lundbeck and Alder BioPharmaceuticals announce updated information in the tender offer materials filed with SEC View HTML Toggle SummaryOct 10, 2019 Alder BioPharmaceuticals® Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of Migraine View HTML Toggle SummarySep 16, 2019 Lundbeck to acquire Alder BioPharmaceuticals – a company committed to transforming migraine treatment and prevention – in a transaction valued at up to USD 1.95 billion net of cash View HTML Toggle SummarySep 05, 2019 Alder BioPharmaceuticals® to Showcase Data from Migraine Prevention Portfolio at 19th Congress of the International Headache Society View HTML Toggle SummaryAug 30, 2019 Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) View HTML Toggle SummaryAug 28, 2019 Alder BioPharmaceuticals® to Present at Two Upcoming September Investor Conferences View HTML Toggle SummaryAug 06, 2019 Alder BioPharmaceuticals® Reports Second Quarter 2019 Financial and Operating Results View HTML Toggle SummaryAug 02, 2019 Alder BioPharmaceuticals® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) View HTML Toggle SummaryAug 01, 2019 Alder BioPharmaceuticals® to Present at Canaccord Genuity 39th Annual Growth Conference View HTML Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
